Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Toll Free Number
CONTACT
Lead
Merck Sharp & Dohme LLC
This study has 2 parts: Part 1 is a dose optimization phase of MK-1045. Part 2 is a randomized phase comparing the efficacy and safety of MK-1045 versus blinatumomab and will use the recommended dose of MK-1045 determined in Part 1
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted